We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
Read MoreHide Full Article
In the latest trading session, TG Therapeutics (TGTX - Free Report) closed at $14.50, marking a -0.89% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.3%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 5.51%.
Heading into today, shares of the biopharmaceutical company had gained 23.67% over the past month, outpacing the Medical sector's loss of 0.54% and the S&P 500's gain of 6.41% in that time.
Wall Street will be looking for positivity from TG Therapeutics as it approaches its next earnings report date. On that day, TG Therapeutics is projected to report earnings of -$0.26 per share, which would represent year-over-year growth of 62.86%. Meanwhile, our latest consensus estimate is calling for revenue of $0.04 million, down 98.28% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for TG Therapeutics. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.82% higher. TG Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
In the latest trading session, TG Therapeutics (TGTX - Free Report) closed at $14.50, marking a -0.89% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.3%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 5.51%.
Heading into today, shares of the biopharmaceutical company had gained 23.67% over the past month, outpacing the Medical sector's loss of 0.54% and the S&P 500's gain of 6.41% in that time.
Wall Street will be looking for positivity from TG Therapeutics as it approaches its next earnings report date. On that day, TG Therapeutics is projected to report earnings of -$0.26 per share, which would represent year-over-year growth of 62.86%. Meanwhile, our latest consensus estimate is calling for revenue of $0.04 million, down 98.28% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for TG Therapeutics. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.82% higher. TG Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.